Cargando…
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted immunologically, but mKRAS epitopes remain poorly defined. Here we e...
Autores principales: | Bear, Adham S., Blanchard, Tatiana, Cesare, Joseph, Ford, Michael J., Richman, Lee P., Xu, Chong, Baroja, Miren L., McCuaig, Sarah, Costeas, Christina, Gabunia, Khatuna, Scholler, John, Posey, Avery D., O’Hara, Mark H., Smole, Anze, Powell, Daniel J., Garcia, Benjamin A., Vonderheide, Robert H., Linette, Gerald P., Carreno, Beatriz M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285372/ https://www.ncbi.nlm.nih.gov/pubmed/34272369 http://dx.doi.org/10.1038/s41467-021-24562-2 |
Ejemplares similares
-
Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer
por: Vonderheide, Robert H., et al.
Publicado: (2020) -
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein
por: Janssen, Kobe, et al.
Publicado: (2023) -
A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein
por: Carver, Joseph, et al.
Publicado: (2014) -
Cancer Immunotherapy with CAR T Cells: Well-trodden Paths and Journey Along Lesser-known Routes
por: Smole, Anze
Publicado: (2022) -
4473 Immune control of plasma cell disorders – in-depth analysis of Sox2 immunity in MGUS
por: Susanibar Adaniya, Sandra Patricia, et al.
Publicado: (2020)